Gov. Kathy Hochul has demonstrated a commitment to accessible health care and drug innovation in New York, but the state’s Drug Utilization Review Board recently voted to pause Medicaid coverage of Sarepta Therapeutics’ FDA-approved gene therapy Elevidys, which has been proven to significantly improve the lives of children with Duchenne muscular dystrophy.
